We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00847795
Recruitment Status : Completed
First Posted : February 19, 2009
Last Update Posted : February 19, 2009
Information provided by:

Study Description
Brief Summary:
An exploratory Phase-II trial with intradermal RN1001 (Avotermin) to investigate scar prevention and reduction and acceleration of healing. The trial has an additional objective to evaluate several different scar assessment techniques that can be used in future clinical trials in the prevention and reduction of scarring.

Condition or disease Intervention/treatment Phase
Cicatrix Drug: Avotermin Drug: Placebo Phase 1 Phase 2

Detailed Description:
Double blind, randomised, Placebo and Standard Care controlled, single centre study. Each subject receives a total of 6 wounds, two incisions and four punch biopsies. Each subject serves as their own control, i.e. Arm 1 incisions/biopsies randomly received one of two treatments and Arm 2 incisions/biopsies received the same treatments as for Arm 1 but in reverse. The randomisation of the treatment allowed for control of possible positional effects on healing/scarring. Healed scars from incisional wounds excised from Arm 1 and Arm 2 after 6 months for histological analysis.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.
Study Start Date : September 2002
Primary Completion Date : June 2003
Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars
Drug Information available for: Avotermin
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
5ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Experimental: 2
50ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Experimental: 3
100ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Placebo Comparator: 4
Drug: Placebo
No Intervention: 5
Standard Care

Outcome Measures

Primary Outcome Measures :
  1. Evaluation of scar appearance by an independent panel [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Histological evaluation of wound healing [ Time Frame: 3 days ]
  2. Adverse event occurance [ Time Frame: 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinically healthy, male and female subjects aged 60 years and over. All females will be at least 2 years post menopausal.
  • Weight between 50 and 150kg or a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15 - 35 kg/m2.

Exclusion Criteria:

  • Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied.
  • Subjects with a personal history of a bleeding disorder.
  • Subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing the acute wounds or involves the areas to be examined in this trial.
  • Subjects with any clinically significant medical condition that would impair wound healing including renal, hepatic, haematological, neurological or immune disease.
  • Subjects with a history of clinically significant drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial.
  • Subjects with any clinically significant abnormality following review of pre trial laboratory data and physical examination (see above).
  • Subjects who are taking, or have taken, any investigational drugs, long term oral, topical or inhaled corticosteroid therapy, hormone replacement therapy (HRT) or anti-coagulant drugs in the thirty days prior to Day 0.
  • Subjects who have evidence of drug abuse.
  • Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibody. Subjects with previous vaccination against Hepatitis B are not excluded per se.
  • Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B core antibody and who show less than 10 units per litre of Anti-HBs.
  • Subjects who have previously had a positive result to the test for HIV antibodies, or who admit to belonging to a high-risk group.
  • In the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00847795

United Kingdom
Renovo CTU
Manchester, United Kingdom, M13 9XX
Sponsors and Collaborators
Principal Investigator: Jonathan Duncan, BS BCh Renovo
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mark Cooper, Renovo Ltd
ClinicalTrials.gov Identifier: NCT00847795     History of Changes
Other Study ID Numbers: RN1001-319-1005
First Posted: February 19, 2009    Key Record Dates
Last Update Posted: February 19, 2009
Last Verified: February 2009

Additional relevant MeSH terms:
Pathologic Processes